Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 12-Week hormone therapy studied for rare tumors

NCT ID NCT05364944

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to measure drug levels in the blood and check safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY GEP-NET

Contacts and locations

Locations

  • AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse

    Marseille, 13385, France

  • AP-HP Hopital Bicetre

    Le Kremlin-Bicêtre, 94270, France

  • CHU Angers

    Angers, 49933, France

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, 20122, Italy

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • Hospital de la Santa Creu i Sant Pau Barcelon

    Barcelona, 08041, Spain

  • Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii

    Warsaw, 03-242, Poland

  • Medicover Praxis fur Neuroendokrinologie

    Munich, 81667, Germany

  • Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita

    Petah Tikva, 49100, Israel

  • Rigshospitalet, Endokrinologisk afdeling

    Copenhagen, 2200, Denmark

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

  • Sheba Medical Center, Endocrine institute

    Ramat Gan, 5265601, Israel

  • University Hospital Coventry, WISDEM Centre, UHCW NHS Trust

    Coventry, CV2 2DX, United Kingdom

  • Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach

    Katowice, 40-514, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.